La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Affimed a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Affimed..

Affimed (NASDAQ:AFMD) Azioni, Catena delle Opzioni

Affimed

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

Affimed NV

News

Offerings

AFMD

Affimed N.V. Files For Mixed Shelf Offering Of Up To $20M

Cantor Fitzgerald analyst Li Watsek reiterates Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) with a Overweight.

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Affimed

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) with a Buy and maintains $10 price target.

Price Target

HC Wainwright & Co. Reiterates Buy on Affimed, Maintains $10 Price Target

Biotech

Guidance

Health Care

General

As Of June 30, 2024, Affimed's Cash, Cash Equivalents And Investments Were €34.4M. Based On Operating And Financial Plans Cash-runway Projected Into H2 2025.

Earnings

Affimed Q2 2024 GAAP EPS €(1.01) Misses €(0.96) Estimate, Sales €154.000K Compared To €1.39M YoY

Management

Affimed Appoints Shawn M. Leland As Chief Executive Officer

Laidlaw &amp; Co. analyst Yale Jen maintains Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) with a Buy and raises the price target from $15 to $25.

Laidlaw & Co. Maintains Buy on Affimed, Raises Price Target to $25

Affimed Anticipates Cash, Equivalents And Short-Term Investments To Support Operations Into H2 2025

Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) reported quarterly losses of $(1.38) per share which beat the analyst consensus estimate of $(1.54) by 10.44 percent. This is a 37.3 percent increase over losses of $(2.20) per share from the same period last year. The company reported quarterly sales of $168.34 thousand which missed the analyst consensus estimate of $1.34 million by 87.44 percent.&nbsp;

Affimed Q1 EPS $(1.38) Beats $(1.54) Estimate, Sales $168.34K Miss $1.34M Estimate

Affimed N.V.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) shares are trading higher on Monday. On Saturday, the company announced longer follow-up data from the&nbsp;EGFRwt cohort and initial clinical efficacy data from the&nbsp;EGFRmut cohort from the ongoing AFM24-102 study in non-small <a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/g39125428/affimed-provides-follow-up-data-of-afm24-plus-atezolizumab-showing-durable-responses-in-heavily-pr" rel="noreferrer noopener">cell lung cancer&nbsp;(NSCLC)</a>.
As of the updated data cutoff on May 13, for the 17&nbsp;EGFRwt patients previously reported, 15 patients were response-evaluable.
Four confirmed objective responses were seen: 1 complete response (CR) and three partial responses (PR).
In addition, eight patients achieved stable disease (SD), resulting in a disease control rate of 71%.
Median progression-free survival was 5.9 months, with a median follow-up of 7.4 months.
3 of 4 responses were ongoing for more than seven months.
All responders were resistant to checkpoint inhibitor treatment before the study, which supports the hypothesis that combining AFM24 with atezolizumab may provide an alternative strategy to overcome resistance to existing therapies.
As of May 21, 2024, 21 heavily pretreated&nbsp;EGFRmut patients had received the combination therapy, of which 13 were response-evaluable.
The combination of AFM24 with atezolizumab showed encouraging signals of clinical activity, including 1 CR, 3 PRs, and six patients with stable disease (SD).
As of the data cutoff, all responses were ongoing. The data suggests that the combination of AFM24 and atezolizumab could be acting synergistically to improve efficacy outcomes.
AFM24 and atezolizumab combination therapy demonstrated a manageable safety profile. The most frequent side effects observed were mild to moderate infusion-related reactions and transient mild to moderate increase in liver enzymes.
The&nbsp;study&#8217;s EGFRwt NSCLC cohort will enroll up to 40 patients, and the&nbsp;EGFRmut NSCLC cohort will enroll up to 25 patients.
Recruitment in both cohorts is ongoing, and further updates are expected in H2 2024.
Price Action: AFMD shares are up 81.4% at $7.89 at last check Monday.
Photo by Aunt Spray via Shutterstock

Movers

Why Is German Biotech Affimed Stock Soaring On Monday?

Shares of Science Applications International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) declined 11% to $119.91 following <a href="https://www.benzinga.com/news/earnings/24/06/39136938/science-applications-international-optimistic-about-hitting-annual-outlook-despite-q1-revenue-dip-s">first-quarter results.</a>
SAIC reported a 9% revenue decline year over year in the fiscal first quarter of 2025 to $1.847 billion, marginally beating the analyst consensus estimate of $1.844 billion. Adjusted EPS of $1.92 was in line with the analyst consensus estimate, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
SAIC shares dipped 11% to $119.91 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Microbot Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) jumped 92.5% to $1.9301 after the company received FDA approval to proceed with its pivotal human clinical trial.</li>
<li>Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares jumped 75% to $3.62. Bio-Path presented interim results from Phase 2 study of Prexigebersen (BP1001) in combination with decitabine and venetoclax for acute myeloid leukemia at the American Society Of Clinical Oncology Annual Meeting.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares climbed 34.5% to $31.13 after Roaring Kitty on a Reddit post, shared his position on the stock.</li>
<li>Professional Diversity Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) gained 28.5% to $0.65. Professional Diversity Network recently named Megan Bozzuto as interim CFO.</li>
<li>MarineMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) gained 27% to $36.16. OneWater Marine Inc. is reportedly said to be in advanced discussions to acquire MarineMax.</li>
<li>Crown ElectroKinetics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) shares rose 27% to $0.1271 after dipping 12% on Friday.</li>
<li>MingZhu Logistics Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>) climbed 26.5% to $0.4425 after the company reported an agreement to acquire Oxylus Global.</li>
<li>Dogness (International) Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOGZ#NASDAQ">DOGZ</a>) gained 23.5% to $13.65</li>
<li>Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) gained 22.2% to $5.25 as the company issued follow-up data of AFM24 plus atezolizumab showing durable responses in heavily pretreated NSCLC EGFR wild-type patients and positive initial data from the NSCLC EGFR mutant cohort.</li>
<li>Concord Medical Services Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) rose 17.6% to $0.5883.</li>
<li>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) rose 17.5% to $4.8001.</li>
<li>Personalis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) gained 17.5% to $1.5282.</li>
<li>Liquidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) gained 16.8% to $15.03 as the company said District Court issued favorable ruling and denied United Therapeutics&#8217; request to block YUTREPIA&#x2122; launch.</li>
<li>Olema Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLMA#NASDAQ">OLMA</a>) rose 15.5% to $11.18.</li>
<li>Stericycle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRCL#NASDAQ">SRCL</a>) gained 15% to $59.28 after the company announced that it entered into a definitive agreement to be acquired by Waste Management.</li>
<li>Precigen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) rose 15% to $1.61 after reporting study data for PRGN-2012 for recurrent respiratory papillomatosis patients.</li>
<li>Coherent Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NASDAQ">COHR</a>) gained 13.4% to $64.71 after the company announced the appointment of Jim Anderson as CEO.</li>
<li>CG Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) rose 11.8% to $36.34</li>
<li>Structure Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) rose 11.8% to $38.25 after the company reported 12-week results for obesity drug GSBR-1290, achieving significant weight loss.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) gained 11.6% to $4.8330. The resumption of the meme rally came on the back of Keith Gill, also known as "Roaring Kitty," disclosing a substantial position in GameStop on the r/Superstonk Reddit forum.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) gained 10.7% to $16.65.</li>
<li>Telephone and Data Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDS#NYSE">TDS</a>) rose 9% to $21.67 as the company agreed to sell its wholly owned subsidiaries OneNeck IT Solutions and OneNeck Data Center to US Signal Company, LLC.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) shares gained 8.8% to $0.6348 after gaining over 3% on Friday. </li>
<li>Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) gained 8.3% to $218.39 after the company issued preliminary results and said there will be no restatement or adjustment of any audited or unaudited financial statements.</li>
<li>Molecular Partners AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares climbed 8.2% to $4.0699. Molecular Partners presented data from completed Phase 1 trial of MP0317 monotherapy in advanced solid tumors at ASCO 2024.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>CalAmp Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares fell 61.4% to $1.03 after the company said it has entered into a Restructuring Support Agreement with its principal secured lender, Lynrock Lake Master Fund LP, who will become the principal equity owner of CalAmp and take the Company private.</li>
<li>Ault Disruptive Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADRT#NASDAQ">ADRT</a>) fell 52.2% to $21.50.</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) fell 32.3% to $0.1463. CNS Pharmaceuticals announced a 1-for-50 reverse stock split.</li>
<li>Galera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTX#NASDAQ">GRTX</a>) fell 30% to $0.1536. Galera Therapeutics will be delisted by Nasdaq.</li>
<li>Portage Biotech Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares fell 29.7% to $0.3365 after gaining over 91% on Friday.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) dipped 29.5% to $0.7895.</li>
<li>FOXO Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NYSE">FOXO</a>) fell 26.3% to $0.3501.</li>
<li>iSpecimen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares declined 24.4% to $0.3251.</li>
<li>Webuy Global Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBUY#NASDAQ">WBUY</a>) fell 23.7% to $0.1870.</li>
<li>Direct Digital Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) fell 21.2% to $2.67.</li>
<li>Vintage Wine Estates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VWE#NASDAQ">VWE</a>) fell 19.2% to $0.2883.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) fell 19.2% to $105.00</li>
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) shares fell 16.4% to $4.55 after jumping over 110% on Friday.</li>
<li>Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) fell 15.1% to $63.00 after the company announced an interim CEO following Jim Anderson&#8217;s decision to step down as President, CEO and Board member to pursue an opportunity with another company.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) dipped 13.8% to $112.00.</li>
<li>Digital Health Acquisition Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAC#NASDAQ">DHAC</a>) shares fell 10.3% to $15.25 after gaining 13% on Friday.</li>
<li>Grupo Aeroportuario del Centro Norte, S.A.B. de C.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMAB#NASDAQ">OMAB</a>) declined 10.2% to $73.44.</li>
<li>Immunocore Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) fell 10.1% to $44.05.</li>
<li>Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAC#NYSE">PAC</a>) fell 10% to $169.23.</li>
<li>GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) fell 8.7% to $40.87 after the company said it will appeal a ruling made by the Delaware State Court regarding its ongoing ranitidine litigation.</li>
<li>The Scotts Miracle-Gro Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) declined 7.7% to $64.33.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) fell 7.7% to $20.81.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) fell 7.1% to $129.63. On May 30, Dell reported upbeat earnings and sales results for the first quarter.</li>
<li>Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) dipped 6.5% to $92.61.</li>
</ul>
The Boston Beer Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) shares fell 4.7% to $299.07. Boston Beer shares jumped around 22% on Friday following a report suggesting the company is in talks to sell itself to Suntory. Boston Beer later issued a statement on the company sale speculation. "We are fully focused on our business as an independent company and our return to growth," the company said.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39137769/this-mongodb-analyst-is-no-longer-bearish-here-are-top-5-upgrades-for-monday">This MongoDB Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday</a>

Intraday Update

Markets

Trading Ideas

ADRT

ADSK

BNAI

BPTH

CAMP

CGON

CNSP

COHR

CRKN

DELL

DHAC

DOGZ

DRCT

EFSH

FFIE

FOXO

GPCR

GRTX

IMCR

IPDN

ISPC

LQDA

LSCC

MBOT

MGNX

MOLN

NVAX

OLMA

Grupo Aeroportuario del Centro NorteB de CV

OMAB

PGEN

PRTG

PSNL

SAIC

SRCL

Vintage Wine Estates, Inc. - Common Stock

WBUY

YGMZ

Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) shares are trading higher Monday after the company announced additional follow-up data from the on-going AFM24-102 study in <a href="https://www.benzinga.com/pressreleases/24/06/g39125428/affimed-provides-follow-up-data-of-afm24-plus-atezolizumab-showing-durable-responses-in-heavily-pr">non-small cell lung cancer (NSCLC).</a>
The Details:
Affimed said in 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved four objective responses, three of four responses were ongoing for more than 7 months and progression free survival (PFS) was 5.9 months.
&#8220;The efficacy of the combination of AFM24 and atezolizumab in these heavily pretreated NSCLC patients is encouraging and supports our hypothesis of a synergistic activity of AFM24 with PD-1/PD-L1 blockade. We believe the durability of the responses in EGFRwt tumors is remarkable and is unlikely driven by PD-1/PD-L1 blockade alone, as all patients with responses had documented progression on their previous PD-1/PD-L1 therapy,&#8221; said Dr. Andreas Harstrick, CEO of Affimed.&nbsp;
HC Wainwright &amp; Co. <a href="https://www.benzinga.com/quote/AFMD/analyst-ratings">reiterated</a> its Buy rating on Affimed and maintained a $10 price target on Monday.&nbsp;
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Affimed shares are trading above the stock&#8217;s 50-day moving average of $5.31 and nearly the stock's entire float of 14.313 million shares has already changed hands in the session.&nbsp;
Related News: <a href="https://www.benzinga.com/news/24/05/39117783/whats-going-on-with-snowflake-stock">What&#8217;s Going On With Snowflake Stock?</a>
<h2 class="wp-block-heading">Should I Sell My AFMD Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Affimed have decreased by 17.48% in the past year. An investor who bought shares of Affimed at the beginning of the year would take a loss of $0.02 per share if they sold it today. The stock has risen 13.48% over the past month, meaning an investor who bought shares on May 1 would see a capital gain of $0.93.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Affimed stock currently has an RSI of 34.92, indicating neutral conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
AFMD Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Affimed shares are up 46.9% at $6.39 at the time of publication Monday.
Image: Mohamed Hassan from Pixabay

Why Affimed Shares Are Soaring

WIIM

Affimed shares are trading higher after the company announced longer follow-up data from the EGFRwt cohort and initial clinical efficacy data from the EGFRmut cohort from the on-going AFM24-102 study in NSCLC.

Affimed Shares Resume Trade

Affimed Shares Halted On Circuit Breaker To The Upside, Stock Now Up 82.1%

Events

Affimed Announced Saturday, In 17 EGFR Wild-type NSCLC Patients Who Failed Chemotherapy And PD-1/PD-l1, AFM24 Plus Atezolizumab Achieved 4 Objective Responses; 3 Of 4 Responses Were Ongoing For More Than 7 Months, Progression Free Survival Was 5.9 Months

This is for the treatment of patients with advanced and/or metastatic non-small cell lung cancer (NSCLC) not harboring any activating EGFR mutations (EGFR&nbsp;wild-type) after progression on PD-(L)1 targeted therapy and platinum-based chemotherapy. Data from the AFM24-102 study in this patient population will be presented at the upcoming annual meeting of the American Society of Clinical Oncology on June 1, 2024.

Affimed Says FDA Granted Fast Track Designation To Combination Of Its Innate Cell Engager AFM24 With Atezolizumab For EGFR Wild-Type Non-Small Cell Lung Cancer

<ul>
<li>Treatment with AFM28 innate cell engager (ICE&#xAE;), designed to target CD123-positive cancer cells in patients with acute myeloid leukemia (AML), led to dose-dependent tumor growth control in a validated in vivo mouse model &nbsp;</li>
<li>AFM28 led to an effective reduction of CD123-expressing AML patient-derived leukemic blasts and stem cells in a newly engineered ex vivo bone marrow niche model</li>
</ul>
MANNHEIM, Germany, May 14, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the publication of an abstract for the annual congress of the European Hematology Association (EHA), taking place in Madrid, Spain, June 13 – 16, 2024. The abstract presents preclinical data of Affimed's CD16A/CD123-targeting ICE&#xAE;, AFM28, in an acute myeloid leukemia (AML) mouse xenograft model and shows that increasing doses of AFM28 lead to a dose-dependent tumor growth control, resulting in an increased median life span of the treated mice compared to controls.
In addition, the abstract shows a data set from a collaboration with Dr. Hind Medyouf's group at the Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany. In a newly engineered ex vivo Human Organotypic Marrow Environment (HOME) model, the combination of AFM28 and allogeneic NK cells can lead to an effective reduction of CD123-expressing AML patient-derived leukemic blasts and stem cells. Importantly, the HOME model exhibits key immune suppressive cellular components, i.e. mesenchymal niche cells, enhancing the translational relevance of AFM28 preclinical activity.

Affimed Announces Acceptance Of An Abstract On Preclinical Data Of Its Innate Cell Engager AFM28 At The EHA 2024 Congress

Affimed N.V. 2024 Q2 - Results - Earnings Call Presentation

Affimed N.V. (AFMD) Q2 2024 Earnings Call Transcript

Affimed (AFMD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from ...

Buy Rating Justified by Promising Clinical Data and Solid Progress in Affimed's Drug Developments

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Affimed (AFMD – Research Report). The company's s...

Truist Financial Reaffirms Their Buy Rating on Affimed (AFMD)

Affimed (AFMD) has released an update. Affimed N.V. invites shareholders to an extraordinary general meeting (EGM) scheduled for October 10, 2024, ...

Affimed N.V. Announces Upcoming EGM

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Affimed (AFMD – Research Report) today. The company's shares closed yester...

Truist Financial Keeps Their Buy Rating on Affimed (AFMD)

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Affimed (AFMD – Research Report) today. The company's shares closed last F...

Truist Financial Sticks to Its Buy Rating for Affimed (AFMD)

Affimed (AFMD) has released an update. Affimed N.V. announced at its Extraordinary General Meeting that shareholders have approved the appointment ...

Affimed Appoints New Director Amid Strategic Moves

Affimed files for $20M mixed securities shelf

13:11 EST Affimed (AFMD) files $20M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...

Affimed files $20M mixed securities shelf

Press Releases

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort

MAIA Biotechnology (MAIA) to Showcase Groundbreaking Telomere-Targeting Cancer Treatments at BIO International Convention 2024

Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024

Affimed Reports First Quarter 2024 Financial Results & Business Update

Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024

Affimed Appoints Shawn M. Leland as Chief Executive Officer

Affimed Reports Second Quarter 2024 Financial Results & Business Update

Affimed to Present at the Cantor Global Healthcare Conference 2024

Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma

Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024

Comments

Affimed

Affimed (AFMD) Opzioni

Affimed (NASDAQ:AFMD) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO